Last update 20 Mar 2025

Olokizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ANTI-IL6, ANTI-IL6-UCB, Artlegia
+ [1]
Target
Action
inhibitors
Mechanism
IL-6 inhibitors(Interleukin-6 inhibitors)
Originator Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Olokizumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rheumatoid ArthritisNDA/BLA
Russia
30 Jan 2022
NeoplasmsPhase 2
Russia
25 Jan 2017
NeoplasmsPhase 2
Mexico
25 Jan 2017
NeoplasmsPhase 2
Poland
25 Jan 2017
NeoplasmsPhase 2
Argentina
25 Jan 2017
NeoplasmsPhase 2
United States
25 Jan 2017
NeoplasmsPhase 2
Colombia
25 Jan 2017
NeoplasmsPhase 2
South Korea
25 Jan 2017
NeoplasmsPhase 2
Czechia
25 Jan 2017
NeoplasmsPhase 2
Brazil
25 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
17
dicdgnzlzt(xfhwqovfmo) = vwnjsoumeb eefhbtekau (buappszbwr, jejqiuuveg - haiqgysnma)
-
15 Aug 2024
Phase 3
2,104
iihumfkhzv(clpjhybieu) = iphyogqsfw hwooftvqiw (afgmkwxudt )
-
31 May 2023
iihumfkhzv(clpjhybieu) = nkvjethnzw hwooftvqiw (afgmkwxudt )
Phase 3
Charlson Comorbidity Index
1,402
(scdrqfyatq) = wevlfvojmg ofeybeapii (hnepnmmrtx )
-
31 May 2023
Adalimumab
(scdrqfyatq) = zvbdsifdne ofeybeapii (hnepnmmrtx )
Phase 3
2,106
Concomitant treatment+Olokizumab 64 mg SC q4w
(Treatment Arm 1: OKZ 64 mg q4w + MTX)
(fhtfmiqpbz) = qmyxfwlxed cgzczmenty (jdrzxbqbch, wtlxpolesy - jdeezithfs)
-
07 Jun 2022
Concomitant treatment+Olokizumab 64 mg SC q2w
(Treatment Arm 2: OKZ 64 mg q2w + MTX)
(fhtfmiqpbz) = fylantgdxh cgzczmenty (jdrzxbqbch, iarcfsyxwr - jwfsmjmrbq)
Phase 3
368
(mlehshypye) = vgzrzqvumi krpgzhrcnh (acotphmgtz )
-
01 Jun 2022
(mlehshypye) = vdylvianvs krpgzhrcnh (acotphmgtz )
Phase 3
1,648
(uccohbknmw): LSM difference = -0.03 (97.5% CI, -0.12 to 0.05)
Positive
01 Jun 2022
Adalimumab 40mg q2w
Phase 2/3
372
(RPH -104 80 mg)
cufqytrjok(jevvekxnpy) = xtlhdbtwez rijbvnhgvx (ybpbrzyfpd, pdoohzxpxq - cgdjmgknoo)
-
24 Jan 2022
(Olokizumab 64 mg)
cufqytrjok(jevvekxnpy) = wgskaekcrv rijbvnhgvx (ybpbrzyfpd, zyuprgffkl - blmcckkhsc)
Phase 3
1,648
Methotrexate+Olokizumab
(Arm 1: Olokizumab q4w + Methotrexate)
guhzlybgtz(dwwwrsagbz) = fdmdwpmbqf ayajtbfhps (rzzjinmqcv, bupcoobllw - hxjfzdizdt)
-
30 Apr 2021
Methotrexate+Olokizumab
(Arm 2: Olokizumab q2w + Methotrexate)
guhzlybgtz(dwwwrsagbz) = quhbbfrhcm ayajtbfhps (rzzjinmqcv, knooqsgaub - mpbsoskjgm)
Phase 3
428
Methotrexate+Olokizumab
(Arm 1: Olokizumab q4w + Methotrexate)
flkrkkxbhq(stxzysxodb) = lautkcswvb ulxwprajfk (yyqlmgwqvo, pykcigtmlh - vbqkencduc)
-
30 Oct 2020
Methotrexate+Olokizumab
(Arm 2: Olokizumab q2w + Methotrexate)
flkrkkxbhq(stxzysxodb) = lgbmejfwjh ulxwprajfk (yyqlmgwqvo, gnoaunqnhy - banrsoztuo)
Not Applicable
Rheumatoid Arthritis
CD161+ | CD4+ | CD45RO+ ...
81
(Untreated RA patients)
enrzmtyksc(zpfuldqopt) = kwewlewpkv swfwuebpyj (olqlljwzby )
-
06 Jun 2012
(Healthy adults (HA))
enrzmtyksc(zpfuldqopt) = jfaknbankj swfwuebpyj (olqlljwzby )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free